Schrödinger

Schrödinger (NASDAQ: SDGR) is a New York-based computational drug discovery and materials science platform company, founded in 1990 and publicly listed since 2020, that combines physics-based molecular simulation with modern machine learning to predict molecular properties, optimise drug candidates, and automate chemical design workflows at scale. All 20 of the world's largest pharmaceutical companies by revenue are customers of the Schrödinger platform, and the company's software generates $201 million in Annual Contract Value on a trailing four-quarter basis.

In Q1 2026 the company reported $58.6 million in total revenue, with drug discovery software revenue rising 124% year-over-year as demand for AI-accelerated drug design reached the mainstream. Schrödinger's strategic advantage is the integration of physics — free energy perturbation (FEP+), molecular dynamics, quantum mechanics — with ML: the physics layer provides ground-truth accuracy for binding affinity and ADMET predictions that pure ML models cannot achieve without experimental validation, while ML accelerates the screening of chemical space.

In 2026 the company unveiled Bunsen, an agentic AI co-scientist designed to autonomously execute complex molecular discovery workflows, enabling researchers to direct multi-step computational campaigns in natural language. Eli Lilly signed a partnership with Schrödinger for AI-driven drug discovery, joining existing collaborations with Bristol Myers Squibb, Takeda, and dozens of other major pharma companies.

The company also has a proprietary drug pipeline with equity-sharing deals: biotech and pharma startups pay royalties and equity stakes worth tens of millions to access the platform for their own pipelines, giving Schrödinger participation in downstream drug value creation.